Speaker: Gerald Li, Regulatory Affairs Director, Elixir Clinical Research
DATE: Thursday August 4 @ 8 pm EDT/5 pm PDT (Note time change to allow for a live presentation with Q&A)
Since 2015, China has experienced pharmaceutical industry reform. There are new regulations, notices and guidance which have been published to optimize the approval process. As one of the key steps in drug development, clinical trials are most cost expending (capital, timing, resources)with a potential for a high risk of failure. In the presentation, Gerald will introduce the clinical study startup component and process in China.
Sponsored by the DIA Regulatory Affairs Community, Regulatory Intelligence WG as part of a series of sessions on the China Regulatory Environment as presented by the DIA China Regulatory Affairs Community
Join Zoom Meeting: https://diaglobal.zoom.us/j/92060156514
Meeting ID: 920 6015 6514
One tap mobile
+16468769923,,92060156514# US (New York)
+16469313860,,92060156514# US
Dial by your location
+1 646 876 9923 US (New York)
+1 646 931 3860 US
+1 301 715 8592 US (Washington DC)
+1 312 626 6799 US (Chicago)
+1 669 444 9171 US
+1 669 900 6833 US (San Jose)
+1 253 215 8782 US (Tacoma)
+1 346 248 7799 US (Houston)
855 880 1246 US Toll-free
877 853 5257 US Toll-free
Meeting ID: 920 6015 6514
Find your local number: https://diaglobal.zoom.us/u/ad567yBOpi
--------------------
https://diaglobal.zoom.us/j/92060156514
https://diaglobal.zoom.us/u/ad567yBOpi